Business
4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
EMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power
About this update from 4d Molecular Therapeutics, Inc.
[{"type":"text","content":"EMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced a presentation on 4D-710 for the treatment of cystic fibrosis lung disease at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting held in Los Angeles, California on May 16-20, 2023. The oral presentation will be given by Jennifer L. Taylor-Cousar, M.D., MSCS, Professor, Departments of Medicine and Pediatrics, and Co-Director, Adult Cystic Fibrosis Program, Director, Cystic Fibrosis Foundation Therapeutics Development Center, National Jewish Health. The presentation will include biomarker data on expression of the cystic fibrosis transmembrane regulator (CFTR) transgene protein from the endobronchial lung biopsies & brushings collected at week 4-8 for patients in Cohort 1 (n=3; dose 1E15 vg) of the Phase 1/2 AEROW clinical trial. In situ hybridization biomarker data, demonstrating transgene RNA expression from lung samples from Cohort 1 patients, was previously presented by Dr. Taylor-Cousar at the North American Cystic Fibrosis Conference (NACFC), November 3, 2022. Additional clinical and biomarker data for Cohort 1 patients (n=3; 9-12 months follow-up) are expected to be presented at the European Cystic Fibrosis Conference in June 2023. Clinical data will focus on safety, tolerability, pulmonary function testing (e.g., percent predicted FEV1) and respiratory-related quality of life assessments. Oral Presentation Details: Presentation Title: AAV Mediated Gene Therapy for Cystic Fibrosis (4D-710)Session Title: Advances in Respiratory and GI Tract Gene and Cell TherapyPresenter: Jennifer L. Taylor-Cousar, M.D., MSCS, Professor, Departments of Medicine and Pediatrics, and Co-Director, Adult Cystic Fibrosis Program, Director, Cystic Fibrosis Foundation Therapeutics Development Center, National Jewish Health; Lead Principal Investigator, 4D-710 Phase 1/2 Clinical TrialDate/Time: Thursday, May 18, 2023, 9:15 a.m. - 9:40 a.m. PT The presentation from the ASGCT annual meeting will also be available on the 4D Molecular Therapeutics website under Scientific Presentations: https://4dmoleculartherapeutics.com/pipeline/#posters-and-publications. About 4D-710 and Cystic Fibrosis Lung Disease 4D-710 i...